| __timestamp | HUTCHMED (China) Limited | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19764000 | 2614539000 |
| Thursday, January 1, 2015 | 67426000 | 3711019000 |
| Friday, January 1, 2016 | 59752000 | 4560733000 |
| Sunday, January 1, 2017 | 65383000 | 5475166000 |
| Monday, January 1, 2018 | 70165000 | 6276700000 |
| Tuesday, January 1, 2019 | 44738000 | 7081200000 |
| Wednesday, January 1, 2020 | 39457000 | 7377200000 |
| Friday, January 1, 2021 | 97894000 | 13634200000 |
| Saturday, January 1, 2022 | 115306000 | 10612500000 |
| Sunday, January 1, 2023 | 453552000 | 11301400000 |
| Monday, January 1, 2024 | 12231500000 |
Unveiling the hidden dimensions of data
In the dynamic world of biopharmaceuticals, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited from 2014 to 2023. Regeneron, a leader in the industry, has consistently outperformed, with its gross profit peaking at approximately $11.3 billion in 2023, marking a 330% increase from 2014. In contrast, HUTCHMED's growth, while more modest, saw a significant surge in 2023, reaching $453 million, a remarkable 2,194% increase from its 2014 figures. This stark contrast highlights Regeneron's robust market position and HUTCHMED's emerging potential. The data underscores the importance of strategic growth and innovation in maintaining competitive advantage in the biopharma sector.
Gross Profit Analysis: Comparing Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.
Amgen Inc. and HUTCHMED (China) Limited: A Detailed Gross Profit Analysis
Gross Profit Analysis: Comparing Sanofi and HUTCHMED (China) Limited
Bristol-Myers Squibb Company and Regeneron Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis
Key Insights on Gross Profit: Bristol-Myers Squibb Company vs HUTCHMED (China) Limited
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited's Expenses
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Gross Profit Trends Compared: Regeneron Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Key Insights on Gross Profit: Catalent, Inc. vs HUTCHMED (China) Limited
Jazz Pharmaceuticals plc and HUTCHMED (China) Limited: A Detailed Gross Profit Analysis
Gross Profit Comparison: Perrigo Company plc and HUTCHMED (China) Limited Trends